Arvinas, Inc.

NasdaqGS:ARVN Stock Report

Market Cap: US$1.3b

Arvinas Management

Management criteria checks 2/4

Arvinas' CEO is John Houston, appointed in Sep 2017, has a tenure of 7.25 years. total yearly compensation is $7.63M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 1.26% of the company’s shares, worth $16.00M. The average tenure of the management team and the board of directors is 0.9 years and 5.2 years respectively.

Key information

John Houston

Chief executive officer

US$7.6m

Total compensation

CEO salary percentage8.6%
CEO tenure7.3yrs
CEO ownership1.3%
Management average tenureless than a year
Board average tenure5.2yrs

Recent management updates

Recent updates

Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Nov 28
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Oct 16

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25
What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13
News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05
There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Feb 24
Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Sep 09

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

CEO Compensation Analysis

How has John Houston's remuneration changed compared to Arvinas's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$309m

Jun 30 2024n/an/a

-US$323m

Mar 31 2024n/an/a

-US$355m

Dec 31 2023US$8mUS$658k

-US$367m

Sep 30 2023n/an/a

-US$295m

Jun 30 2023n/an/a

-US$298m

Mar 31 2023n/an/a

-US$301m

Dec 31 2022US$10mUS$632k

-US$282m

Sep 30 2022n/an/a

-US$253m

Jun 30 2022n/an/a

-US$233m

Mar 31 2022n/an/a

-US$213m

Dec 31 2021US$13mUS$584k

-US$191m

Sep 30 2021n/an/a

-US$180m

Jun 30 2021n/an/a

-US$164m

Mar 31 2021n/an/a

-US$139m

Dec 31 2020US$8mUS$564k

-US$119m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$86m

Mar 31 2020n/an/a

-US$78m

Dec 31 2019US$5mUS$528k

-US$70m

Sep 30 2019n/an/a

-US$65m

Jun 30 2019n/an/a

-US$173m

Mar 31 2019n/an/a

-US$179m

Dec 31 2018US$6mUS$428k

-US$240m

Sep 30 2018n/an/a

-US$233m

Jun 30 2018n/an/a

-US$114m

Mar 31 2018n/an/a

-US$98m

Dec 31 2017US$954kUS$371k

-US$29m

Compensation vs Market: John's total compensation ($USD7.63M) is above average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Houston (64 yo)

7.3yrs

Tenure

US$7,627,032

Compensation

Dr. John G. Houston, Ph.D. serves as Independent Director at NextCure, Inc. since September 10, 2020. He has been President, Chief Executive Officer and Director of Arvinas, Inc. since September 20, 2017 a...

Leadership Team

NamePositionTenureCompensationOwnership
John Houston
Chairperson7.3yrsUS$7.63m1.26%
$ 16.0m
Ian Taylor
President of Research & Development and Chairman of Scientific Advisory Boardless than a yearUS$2.73m0.14%
$ 1.7m
Andrew Saik
CFO & Treasurerless than a yearno datano data
Angela Cacace
Chief Scientific Officerless than a yearno data0.018%
$ 222.9k
Jared Freedberg
General Counsel & Corporate Secretaryless than a yearno datano data
Steve Weiss
Senior VP & Chief Human Resources Officerno datano datano data
Randy Teel
Chief Business Officerless than a yearno data0.021%
$ 263.5k
John Northcott
Chief Commercial Officer2.3yrsno datano data
Lisa Sinclair
Senior Vice President of Corporate Operations2.3yrsno datano data
Paul McInulty
Senior Vice President of Regulatory Affairs2.2yrsno datano data
Kelly Page
Senior VP & Global Head of Oncology Strategy and Program Leadership1.8yrsno datano data
Noah Berkowitz
Chief Medical Officerless than a yearno datano data

0.9yrs

Average Tenure

55yo

Average Age

Experienced Management: ARVN's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
John Houston
Chairperson7.3yrsUS$7.63m1.26%
$ 16.0m
Ian Taylor
President of Research & Development and Chairman of Scientific Advisory Boardless than a yearUS$2.73m0.14%
$ 1.7m
Edward Kennedy
Independent Director6.4yrsUS$422.69k0.068%
$ 865.6k
Lillian Siu
Member of Scientific Advisory Board5.2yrsno datano data
Leslie Norwalk
Independent Director5.4yrsUS$424.99k0.0060%
$ 76.2k
Briggs W. Morrison
Lead Independent Director6.5yrsUS$441.76k0.035%
$ 445.3k
Laurie Smaldone Alsup
Independent Director5.1yrsUS$430.30k0.0060%
$ 76.2k
Adam Boxer
Member of Scientific Advisory Board5.2yrsno datano data
Lennart Mucke
Member of Scientific Advisory Board5.2yrsno datano data
Benjamin Neel
Member of Scientific Advisory Board5.2yrsno datano data
John Young
Independent Director2.3yrsUS$422.49k0.0060%
$ 76.2k
Linda Bain
Independent Director4.5yrsUS$434.99k0.0060%
$ 76.2k

5.2yrs

Average Tenure

62.5yo

Average Age

Experienced Board: ARVN's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:13
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arvinas, Inc. is covered by 30 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
null nullBMO Capital Markets Equity Research
Etzer DaroutBMO Capital Markets Equity Research